Inclusion Criteria:

1. Patients with histologically documented diagnosis of advanced stage IV or
unresectable stage III mucosal or cutaneous melanoma are eligible.

2. They must have recurrent melanoma with measurable or evaluable sites of disease, 1.0
cm or larger, in order to assess the response to treatment by the immune-related
response criteria (irRC).

3. Patients should not have been previously treated with cytotoxic drugs and
immunotherapeutic agents for unresectable Stage III or Stage IV disease. Prior
Ipilimumab in metastatic setting is not allowed. Prior therapy may include one line
of targeted therapy for metastatic disease ie BRAF or MEK inhibitor. Prior adjuvant
interferon is permitted. Prior cytotoxic therapy in adjuvant or metastatic setting is
not allowed. Prior Ipilimumab in adjuvant setting is not allowed. Prior adjuvant
therapy with targeted therapy including but not limited to B-RAF, MEK inhibitors etc.
is allowed. Prior palliative radiation therapy for metastatic melanoma is permitted
provided the patient has unirradiated metastatic sites for response evaluation and
has fully recovered from its toxicity.

4. Patients between 12 years of age and 70 years of age with an ECOG performance status
of 0 or 1 will be eligible

5. They should have normal blood counts with a white blood cell count of more than or
equal to 3000/mm^3 an absolute neutrophil count of more than or equal to 1500/mm^3
and a platelet count of more than 100,000/mm^3, Hemoglobin > 9.0 g/dL and have no
impairment of renal function (serum creatinine less than 1.1 mg/dl for females and
less than 1.4 mg/dl for males), hepatic function (serum bilirubin level of less than
1.5 mg/dl, AST and ALT case AST and ALT of significant cardiac or pulmonary dysfunction.

6. They should have no significant intercurrent illness such as an active infection
associated with fever lasting more than 24 hours requiring antibiotics, uncontrolled
psychiatric illness, hypercalcemia (calcium greater than 11 mg), or active GI
bleeding. Females of child-bearing potential (non-childbearing is defined as greater
than one year post-menopausal or surgically sterilized) must use acceptable
contraceptive methods( abstinence, intrauterine device, oral contraceptive or double
barrier devices) and must have a negative serum or urine pregnancy test within 72
hours prior to beginning treatment on this trial. Sexually active men must also use
acceptable contraceptive methods for the duration of time on study and signed
informed consent .

Exclusion Criteria:

1. Patients with metastatic uveal melanoma

2. Patients with bone metastases only.

3. Patients with symptomatic brain or spinal cord metastases or requiring steroid
therapy and patients with leptomeningeal disease. Patients with treated and stable
CNS metastasis for 3 months or more, off steroids are eligible for the study. No
major surgery or radiation therapy within 21 days before starting treatment.

4. Patients with significant cardiac illness such as symptomatic coronary artery disease
or previous history of myocardial infarction, impaired left ventricle function
(Ejection Fraction less than 50%) on account of any organic disease such as
hypertension or valvular heart disease or serious cardiac arrhythmia requiring
therapy. Patients with significant history of cardiac disease will be evaluated by
the investigator or his designee.

5. Patients with significant impairment of pulmonary function on account of chronic
bronchitis, emphysema or chronic obstructive pulmonary disease (COPD) which has
resulted in impairment of vital capacity of FEV1 to less than 75% of predicted normal
values.

6. Patients with symptomatic effusions on account of pleural, pericardial or peritoneal
metastases of melanoma.

7. Patients who are unable to return for follow-up visits as required by this study.
Patients with a history of second malignant tumor, other than the common skin cancers
- basal and squamous carcinomas, within the past 3 years and uncertainty about the
histological nature of the metastatic lesions. Cases with other types of malignancies
should be reviewed and decided by the PI of the study.

8. Patients with ≥ grade 2 sensory neuropathy at baseline.

9. Patients who have had major surgery or radiation therapy within 21 days of starting
treatment.